LeMaitre Vascular, Inc. (LMAT) Stock Forecast
LMAT analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.75 / 5 from 8 analysts
- Price target
- $107.00 average of analyst targets
- Upside to target
- +32.4% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.69
- 52-week range
- $78.80 – $117.39
LMAT analyst ratings
8 analystsNumber of analysts at each rating.
LMAT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LMAT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.69 | $0.68 | $0.69 | $0.75 | −8.5% | 8 |
| Current fiscal year (2026) | $2.88 | $2.84 | $2.90 | $2.52 | +14.2% | 8 |
| Next fiscal year (2027) | $3.18 | $3.04 | $3.30 | $2.88 | +10.4% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LMAT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $67.4M | $67.2M | $67.9M | +10.4% | 8 |
| Current fiscal year (2026) | $276.5M | $276.0M | $277.3M | +10.8% | 8 |
| Next fiscal year (2027) | $302.9M | $299.0M | $306.5M | +9.5% | 8 |
LMAT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LMAT revenue: reported and forecast
LMAT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.73 | $0.69 | $0.69 | $0.69 | $0.69 | −6.4% | 0 up · 8 down |
| Current fiscal year (2026) | $3.00 | $2.88 | $2.88 | $2.88 | $2.88 | −4.0% | 0 up · 8 down |
| Next fiscal year (2027) | $3.26 | $3.18 | $3.18 | $3.18 | $3.18 | −2.4% | 0 up · 7 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LMAT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LMAT beat in 10 of 12.
What analysts expect from LMAT
8 analysts cover LeMaitre Vascular; their consensus rating is buy (3.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $107.00, 32.4% above the latest close of $80.82. Analysts expect earnings of $2.88 per share for 2026, +14.2% from a year earlier. For 2027 the average estimate is $3.18 per share on revenue of $302.9 million. LeMaitre Vascular beat the EPS estimate in 10 of the last 12 quarters.
Related: LMAT income statement, LMAT key metrics, LMAT chart. See the LMAT stock overview for the latest quote and news.
LMAT forecast FAQ
What is LeMaitre Vascular's price target?
The average analyst price target for LeMaitre Vascular is $107.00, 32.4% above the latest close of $80.82.
Is LeMaitre Vascular a buy, hold or sell?
Of 8 analysts covering LeMaitre Vascular, 2 rate it a strong buy, 2 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is LeMaitre Vascular's EPS forecast?
Analysts forecast $2.88 per share for 2026 (range $2.84 to $2.90); for 2027 the estimate is $3.18.
What is LeMaitre Vascular's revenue forecast?
The average revenue estimate for 2026 is $276.5 million, growth of 10.8%; for 2027 it is $302.9 million.
When does LeMaitre Vascular report earnings?
LeMaitre Vascular is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $0.69.
Does LeMaitre Vascular usually beat earnings estimates?
LeMaitre Vascular reported EPS at or above the analyst estimate in 10 of the last 12 quarters.